Paper Details

  1. Home
  2. Paper Details

Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.

Author: KriegsmannKatharina, KriegsmannMark, Witzens-HarigMathias

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ibrutinib is a first-generation Bruton's tyrosine kinase (BTK) inhibitor used to treat B-cell malignancies. Acalabrutinib is a second-generation BTK inhibitor with a more selective profile. While acalabrutinib has shown promising results in clinical trials, further research is needed to directly compare its efficacy and safety to ibrutinib and to explore its use in combination therapies.
Paper Details　
Original Abstract of the Article :
The Bruton's tyrosine kinase (BTK) is an essential in the B-cell receptor (BCR) signaling pathway which was identified as crucial in the pathogenesis of B-cell malignancies. Ibrutinib, a first-in-class BTK inhibitor, has been approved for the treatment of distinct B-cell malignancies. To overcome of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/978-3-319-91439-8_14

データ提供：米国国立医学図書館（NLM）

Acalabrutinib: A New Hope in the Desert of B-Cell Malignancies

B-cell malignancies, a group of cancers affecting the immune system, can be like a relentless desert storm, threatening to overwhelm the body. This study focuses on acalabrutinib, a novel second-generation Bruton's tyrosine kinase (BTK) inhibitor, that has shown promise in treating these cancers. BTK is a key protein involved in the signaling pathway of B-cells, and inhibiting it can effectively target these cancers. Acalabrutinib has demonstrated promising safety and efficacy profiles in clinical trials for patients with relapsed chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The drug has been approved for the treatment of adult patients with MCL who have received at least one prior therapy. While acalabrutinib holds significant promise, further research is needed to compare its effectiveness to other BTK inhibitors and to explore its use in combination with other therapies.

A New Oasis in the Desert: Targeted Therapy for B-Cell Malignancies

This study offers a glimmer of hope for patients with B-cell malignancies, demonstrating the potential of acalabrutinib, a novel second-generation BTK inhibitor, to effectively target these cancers. The findings suggest that acalabrutinib could be a valuable addition to the arsenal of treatments for these challenging diseases, offering a more targeted and effective approach.

Navigating the Desert of B-Cell Malignancies: A New Path to Recovery

This study highlights the potential of acalabrutinib, a novel BTK inhibitor, to provide a more targeted and effective treatment for patients with B-cell malignancies. The findings offer hope for a future where these challenging diseases are managed with greater precision and effectiveness, improving the lives of patients and offering a brighter outlook for recovery.

Dr.Camel's Conclusion

This study explores the potential of acalabrutinib, a novel second-generation BTK inhibitor, as a promising treatment option for patients with B-cell malignancies. The findings suggest that acalabrutinib could be a valuable addition to the arsenal of treatments for these challenging diseases, offering a more targeted and effective approach.
Date :
  1. Date Completed 2019-05-20
  2. Date Revised 2019-05-20
Further Info :

Pubmed ID

30069636

DOI: Digital Object Identifier

10.1007/978-3-319-91439-8_14

Related Literature

Article Analysis
・Side Effects of acalabrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.